An observational study published in the Journal of Heart and Lung Transplantation in April revealed that Actelion’s oral Uptravi (selexipag) is safe and well-tolerated in children with pulmonary arterial hypertension when administered as an add-on treatment. Selexipag is currently the only prostacyclin receptor agonist approved to target the prostacyclin pathway in adults with pulmonary arterial hypertension.
According to GlobalData, youths under age 18 years had a higher number of adjusted incident cases of pulmonary arterial hypertension in the six major markets in 2019 compared to the 18–19 years old age group. Read more here.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
